Despite significant advancements in understanding the genetic basis of cancer, translating this knowledge into effective personalized medicine remains challenging.  Identifying the complete spectrum of somatic mutations driving individual tumorigenesis is hampered by the heterogeneity within and between tumors, requiring comprehensive genomic profiling techniques that are both costly and technically demanding.  Furthermore,  interpreting the functional significance of identified mutations presents a significant hurdle.  While some driver mutations are well-characterized, many variants of unknown significance (VUS) complicate prognosis and treatment selection.  The dynamic nature of cancer, with evolving mutational landscapes and potential for acquired drug resistance, necessitates longitudinal monitoring of genomic alterations, adding complexity and cost to personalized treatment strategies.  Moreover,  developing effective targeted therapies against specific mutations often encounters difficulties due to the complexity of cellular signaling pathways and the potential for off-target effects.  Ultimately, the integration of genomic data with clinical information and the development of robust predictive models remain critical but underdeveloped aspects of realizing the full potential of personalized cancer medicine.  Overcoming these experimental challenges is crucial for improving patient outcomes through truly tailored treatment approaches.